JP2025502095A - 移植拒絶反応のリスクを処置または低減する方法 - Google Patents

移植拒絶反応のリスクを処置または低減する方法 Download PDF

Info

Publication number
JP2025502095A
JP2025502095A JP2024541033A JP2024541033A JP2025502095A JP 2025502095 A JP2025502095 A JP 2025502095A JP 2024541033 A JP2024541033 A JP 2024541033A JP 2024541033 A JP2024541033 A JP 2024541033A JP 2025502095 A JP2025502095 A JP 2025502095A
Authority
JP
Japan
Prior art keywords
administered
days
hours
months
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541033A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023133577A5 (https=
JP2025502095A5 (https=
Inventor
パオリーニ，ジョン・エフ
モヒウディン，ムハンマド・エム
Original Assignee
キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
ユニバーシティー オブ メリーランド，ボルティモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング, ユニバーシティー オブ メリーランド，ボルティモア filed Critical キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2025502095A publication Critical patent/JP2025502095A/ja
Publication of JPWO2023133577A5 publication Critical patent/JPWO2023133577A5/ja
Publication of JP2025502095A5 publication Critical patent/JP2025502095A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024541033A 2022-01-10 2023-01-10 移植拒絶反応のリスクを処置または低減する方法 Pending JP2025502095A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263298133P 2022-01-10 2022-01-10
US63/298,133 2022-01-10
US202263307911P 2022-02-08 2022-02-08
US63/307,911 2022-02-08
US202263327986P 2022-04-06 2022-04-06
US63/327,986 2022-04-06
PCT/US2023/060358 WO2023133577A1 (en) 2022-01-10 2023-01-10 Methods of treating or reducing risk of transplant rejection

Publications (3)

Publication Number Publication Date
JP2025502095A true JP2025502095A (ja) 2025-01-24
JPWO2023133577A5 JPWO2023133577A5 (https=) 2026-01-20
JP2025502095A5 JP2025502095A5 (https=) 2026-01-20

Family

ID=87074361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541033A Pending JP2025502095A (ja) 2022-01-10 2023-01-10 移植拒絶反応のリスクを処置または低減する方法

Country Status (8)

Country Link
US (1) US20230287132A1 (https=)
EP (1) EP4463182A1 (https=)
JP (1) JP2025502095A (https=)
KR (1) KR20240131437A (https=)
AU (1) AU2023205152A1 (https=)
CA (1) CA3242941A1 (https=)
MX (1) MX2024008562A (https=)
WO (1) WO2023133577A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
WO2017040932A1 (en) * 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2023133577A1 (en) 2023-07-13
KR20240131437A (ko) 2024-08-30
AU2023205152A1 (en) 2024-07-18
MX2024008562A (es) 2024-12-06
US20230287132A1 (en) 2023-09-14
CA3242941A1 (en) 2023-07-13
EP4463182A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
US20230287132A1 (en) Methods of treating or reducing risk of transplant rejection
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
JP5722524B2 (ja) 補体活性を抑制することによる同種移植片の生存の延長
US12240894B2 (en) Methods of treating AL amyloidosis
US20240052062A1 (en) Reducing surgery-associated hemolysis in cold agglutinin disease patients
CN116783216A (zh) 用于诱导耐受性的方法和组合物
CN118891285A (zh) 治疗移植物排斥或降低移植物排斥风险的方法
US20250084153A1 (en) Methods of treating al amyloidosis
US20250345418A1 (en) Methods of treating al amyloidosis
TW202606724A (zh) 器官移植中缺血再灌注損傷之治療或預防
TW202547553A (zh) 治療ａｌ類澱粉變性症之方法
JP2025532869A (ja) 慢性腎疾患を有する患者における心臓手術関連急性腎損傷（ｃｓａ－ａｋｉ）及び／又はその後の主要な腎臓有害事象（ｍａｋｅ）を予防又は最小化するための抗ｃ５抗体の投薬及び投与
JP2025126668A (ja) 人免疫グロブリンｇを有効成分として含有する、腎臓移植後の抗体関連型拒絶反応の治療剤
EP4021457A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
US9682071B2 (en) Methods of improving microvascular integrity
WO2023107100A1 (en) Methods and treatment for multiple myeloma involving antibodies to il-18
EA044759B1 (ru) Лечение и профилактика амилоидоза

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240910

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240909

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260108